Contraception or Complication: A Review of Depo-Provera’s Pharmacology and Public Health Implication

This review article explores the link between progestogens and meningioma risk and outlines the biological mechanisms that may contribute to tumorigenesis. Two progestogens are emphasized through the paper: cyproterone acetate and medroxyprogesterone acetate (Depo-Provera). An important French study examining the relationship between progestogens use and meningioma risk is discussed, along with the health risks associated with long-term use. Additionally, this review advocates for increased routine prescriber-patient consultations and stronger drug regulation to educate and protect patients, particularly those experiencing socioeconomic disadvantages. It is important to note that the FDA recently updated the label for injectable medroxyprogesterone acetate in December 2025 to include a meningioma warning. Furthermore, continued efforts to promote clear and comprehensive drug labeling remain vital.